Immunotherapy for PLC would stimulate the body’s immune response to tumor cells and regulate the immune microenvironment of PLC through various ways of immune activation, so as to achieve the anti-tumor effect through the interaction of immune cells and molecules (Cao et al., 2005; Cantor et al., 2013; Rizzo et al., 2021a). This evidence concerns the gene HSPG2 and neoplasm.